Table. Clinical trials of EGFR-TKI in EGFR mutated NSCLC
Authors |
Numbers of patients |
Groups |
mOS(month) |
P value |
mPFS(month) |
P value |
ORR |
P value |
MokTS [11] |
261 |
Gefitinib |
|
|
10 |
P<0.001 |
71.20% |
P<0.001 |
|
|
Carboplatin + paclitaxel |
|
|
7 |
|
47.30% |
|
Maemondo M [12] |
230 |
Gefitinib |
30.5 |
P<0.001 |
10.8 |
P<0.001 |
73.70% |
P<0.001 |
|
|
Carboplatin + paclitaxel |
23.6 |
|
5.4 |
|
30.70% |
|
Sun JM [14] |
33 |
Gefitinib |
|
|
15.7 |
P<0.01 |
87.50% |
P<0.01 |
|
|
Pemetrexed |
|
|
2.9 |
|
38.90% |
|
Mitsudomi T [15] |
172 |
Gefitinib |
|
|
9.2 |
P<0.0001 |
62.10% |
P<0.0001 |
|
|
Docetaxel |
|
|
6.3 |
|
32.20% |
|
Wu YL [16] |
217 |
Erlotinib |
26.3 |
P=0.607 |
11 |
P<0.0001 |
62.70% |
P<0.0001 |
|
|
Gemcitabine + cisplatin |
25.5 |
|
5.5 |
|
33.60% |
|
Zhou C [17, 18] |
154 |
Erlotinib |
22.8 |
P=0.2663 |
13.1 |
P<0.0001 |
83% |
P<0.0001 |
|
|
Standard chemotherapy |
27.2 |
|
4.6 |
|
36% |
|
Rosell R [21] |
174 |
Erlotinib |
19.3 |
P=0.87 |
9.7 |
P<0.0001 |
|
|
|
|
Standard chemotherapy |
19.5 |
|
5.2 |
|
|
|
Wu YL [23] |
364 |
Afatinib |
|
|
11 |
P<0.0001 |
66.90% |
P<0.0001 |
|
|
Cisplatin + gemcitabine |
|
|
5.6 |
|
23% |
|
Sequist LV [24] |
345 |
Afatinib |
|
|
11.1 |
P=0.001 |
56% |
P=0.001 |
|
|
Cisplatin + pemetrexed |
|
|
6.9 |
|
23% |
|
Wu YL& Mok TS [26, 27] |
452 |
Dacomitinib |
34.1 |
P=0.0438 |
14.7 |
P<0.0001 |
75% |
P=0.2224 |
|
|
Gefitinib |
26.8 |
|
9.2 |
|
70% |
|
Soria JC& Ramalingam SS [28, 29] |
556 |
Osimertinib |
38.6 |
P=0.046 |
18.9 |
P<0.001 |
80% |
P=0.24 |
|
|
Gefitinib |
31.8 |
|
10.2 |
|
76% |
|
Mok TS [30] |
419 |
Osimertinib |
|
|
10.1 |
P<0.001 |
71% |
P<0.001 |
|
|
Pemetrexed + Carboplatin / cisplatin |
|
|
4.4 |
|
31% |
|